Pharmaceuticals - Indian - Formulations
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 36.30 | 52.94 | 73 | 56.21 | 24.26 |
Total Expenses | 37.51 | 54.86 | 60.64 | 54.06 | 22.79 |
Profit Before Tax | -1.21 | -4.16 | 12.36 | 2.14 | 1.47 |
Profit After Tax | -1.68 | -2.68 | 11.38 | 1.40 | 1.10 |
Operating Profit after Depreciation | -0.99 | -1.49 | 12.83 | 3.28 | 2.19 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 2.91 | 3.31 | 2.83 | 4.43 | 4.98 |
Total Non Current Assets | 8.96 | 8.08 | 3.72 | 16.18 | 12.70 |
Total Current Assets | 24.68 | 20.08 | 38.23 | 22.54 | 22.68 |
TOTAL ASSETS | 33.63 | 28.16 | 41.95 | 38.72 | 35.38 |
Total Shareholder's Fund | 21.86 | 23.21 | 24.17 | 13.69 | 12.56 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | 4.85 | -1.56 | 8.26 | 1.83 | -15.18 |
Net Cash used in Investing Activities | -1.79 | -4.28 | -1.13 | -0.31 | -0.01 |
Net Cash used in Financing Activities | -1.17 | -2.15 | 1.30 | 3.99 | 16.36 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Total Revenue | 3.55 | 0.84 | 1.03 | 1.12 | 1.44 |
Total Expenses | 3.53 | 1.24 | 0.68 | 1.02 | 1.27 |
Profit Before Tax | 0.03 | -2.64 | 0.36 | 0.10 | 0.17 |
Profit After Tax | 0.02 | -2.62 | 0.36 | 0.10 | 0.17 |
Operating Profit after Depreciation | 0.03 | -0.40 | 0.36 | 0.12 | 0.17 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Fixed Assets | 0.10 | 0.12 | 0.33 | 0.26 | 0.11 |
Total Non Current Assets | 8.79 | 8.81 | 9 | 8.67 | 8.52 |
Total Current Assets | 3.97 | 0.18 | 2.60 | 2.73 | 3.13 |
TOTAL ASSETS | 12.76 | 8.99 | 11.60 | 11.40 | 11.65 |
Total Shareholder's Fund | 8.93 | 8.90 | 11.52 | 11.16 | 11.07 |
Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
---|---|---|---|---|---|
Net Cash from Operating Activities | -0.03 | -0.08 | 0.55 | 0.27 | -0.01 |
Net Cash used in Investing Activities | - | 0.09 | -0.38 | -0.19 | -0.07 |
Net Cash used in Financing Activities | - | - | -0.14 | -0.09 | 0.09 |
Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
---|---|---|---|---|---|
Total Revenue | 5.80 | 5.87 | 7.44 | 10.59 | 8.29 |
Total Expenses | 6.44 | 7.20 | 6.13 | 9.38 | 8.15 |
Profit Before Tax | -0.59 | -1.33 | 1.36 | 1.16 | 0.02 |
Profit After Tax | -0.59 | -1.33 | 0.95 | 1.20 | 0.01 |
Operating Profit after Depreciation | -0.47 | -1.21 | 1.47 | 1.48 | 0.14 |
Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
---|---|---|---|---|---|
Total Revenue | 0.16 | 0.08 | 0.38 | 3.36 | 0.17 |
Total Expenses | 0.25 | 0.16 | 0.51 | 3.23 | 0.09 |
Profit Before Tax | -0.09 | -0.06 | -0.13 | 0.14 | 0.08 |
Profit After Tax | -0.09 | -0.06 | -0.13 | 0.13 | 0.09 |
Operating Profit after Depreciation | -0.09 | -0.06 | -0.13 | 0.14 | 0.08 |
Company | Price | Market Cap (in ₹ Cr) |
---|---|---|
Decipher Labs Ltd | ₹11.99 | ₹12.11 |
Sun Pharmaceuticals Industries Ltd | ₹1,701.55 | ₹4,08,258.84 |
Divis Laboratories Ltd | ₹5,835.60 | ₹1,54,916.84 |
Cipla Ltd | ₹1,482.20 | ₹1,19,704.55 |
Torrent Pharmaceuticals Ltd | ₹3,046.30 | ₹1,03,096 |
Dr Reddys Laboratories Ltd | ₹1,197.85 | ₹99,951.47 |
On 13 February 2025
08 Feb 2025, 01:40 pm
On 14 November 2024
09 Nov 2024, 11:35 am
On 30 September 2024
16 Sep 2024, 10:28 am
On 30 September 2024
14 Sep 2024, 05:34 pm
On 14 August 2024
12 Aug 2024, 02:38 pm